Davita Inc vs Mercadolibre Inc — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while Mercadolibre Inc trades at $1,889.85 (market cap $94.13B). The key difference: Mercadolibre Inc is far larger — about 8.3× Davita Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Mercadolibre Inc for 117 Days on average.
| DVA | MELI | |
|---|---|---|
Market Cap | $11.29B | $94.13B |
Volume | 582,204 | 273,781 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $2.36K |
52-Week Low | $103.87 | $1.55K |
Typical Hold Time | 114 Days | 117 Days |
Enterprise Value | $24.01B | $101.77B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, up 0.14% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 15 and revenue growth from $13.64B in 2025 to projected $14.0B in 2026. Recent news highlights value-based care expansion with Humana and institutional buying by BlackRock. Technical indicators show resistance at $179 and support at $175, with RSI neutral at 59.72.
DVA presents a mixed outlook: analyst consensus targets $235.67 (33% upside) with 43% buy ratings, but technicals suggest near-term pressure. Key opportunities include consistent EPS beats and partnership growth, while risks involve rising debt-to-asset ratio (65.55% in 2025) and regulatory exposure. Net cash flow turned negative in 2025, requiring monitoring.
MercadoLibre (MELI) trades at $1,856.66, down 0.86% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $28.89 billion in 2025, though net income margins dipped to 6.91%. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy business growth, while its fintech credit portfolio surged 75% in Q2 2026 to $16.4 billion.
Outlook remains positive with analyst consensus at 'Buy' and a $2,170 price target, but risks include profit margin pressure and macroeconomic headwinds in Latin America. The stock's high P/E of 50.51 suggests growth expectations are priced in, requiring sustained execution to justify valuation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →